Lite Strategy (LITS) risk factors, FY2026 10-K

Lite Strategy's FY2026 10-K, filed Sep 28, 2026, lists 27 risk factors in 5 groups. Against the prior year's 29: 1 new, 3 dropped, 6 substantially reworded.

Risk factors listed
275 groups
New this year
1vs 29 last year
Dropped
3since the prior 10-K
Substantially reworded
6of those kept
Section length
9k wordsItem 1A

What the changes say

  • Lite Strategy now emphasizes its Litecoin Treasury Strategy and exposure to LTC price volatility alongside potential pre-clinical drug programs.
  • Capital needs now cover both Litecoin treasury execution and drug development, while three drug-development risks were removed.
  • Warrant exposure increased to 3,406,839 shares plus 546,348 Pre-Funded Warrants, and options increased to 1,731,085 shares.
  • Crypto regulation and market risks remain, with the SEC’s March 17, 2026 Digital Asset Interpretation added to the disclosure.

What changed since the prior 10-K

New

  • NewRisks Related to Our Financial Condition and Capital Requirements

    We may need to raise additional capital to continue such development of our pre-clinical drug development programs or our Litecoin Treasury Strategy

    Cash may run out sooner than expected, requiring funding for the Litecoin Treasury Strategy, drug programs, intellectual property, or future collaborations.

Dropped

  • DroppedRisks Related to Our Financial Condition and Capital Requirements

    Should we resume development activities in the future, we expect that R&D costs would increase and we would continue to incur expenses and operating and net losses, as we develop and seek development and/or commercial relationships with other partners for such drug candidates

  • DroppedRisks Related to Our Financial Condition and Capital Requirements

    Whenever we resume development of our drug candidates or any future drug candidate, we may need to raise additional capital to continue such development

  • DroppedRisks Related to Any Future Development and Commercialization of Our Drug and Potential Drug Candidates

    Should we resume development of our drug candidate or future drug candidates, if we are unable to successfully complete clinical development, obtain regulatory approvals and commercialize our drug candidate or future drug candidates, or experience significant delays in doing so, our business will be materially harmed

Reworded

  • 89% rewrittenRisks Related to Our Financial Condition and Capital Requirements

    We have incurred significant losses from our inception and we anticipate that we may incur losses in the foreseeable future

    The company now highlights nononcologic pre-clinical programs and LTC holdings, adding exposure to LTC price fluctuations; prior-year loss figures were removed.

  • 62% rewrittenGeneral Business Risks

    Security breaches and privacy, data protection, cybersecurity, operational resilience and Artificial Intelligence (AI) issues could compromise our information and systems and expose us to liability, which would cause our business and reputation to suffer

    The disclosure now covers personal data of other counterparties and omits the prior-year detail about increasing cyberattack frequency, sophistication, and intensity.

    Was: Security breaches and privacy issues could compromise our information and expose us to liability, which would cause our business and reputation to suffer

  • 55% rewrittenRisks Related to Securities Markets and Investment in our Stock

    Future sales of our common stock, including common stock issued upon exercise of outstanding warrants or options, may depress the market price of our common stock and cause stockholders to experience dilution

    Warrants increased from 3,070,177 at a $4.10 weighted-average exercise price to 3,406,839 at $3.90, plus 546,348 Pre-Funded Warrants; options increased to 1,731,085.

  • 45% rewrittenRisks Related to Securities Markets and Investment in our Stock

    We are currently operating in a period of capital markets disruption and economic uncertainty

    The examples shifted from COVID-19, banking failures, Ukraine, and elections to shutdowns, tariffs, high rates, supply disruptions, and additional geopolitical conflicts.

  • 42% rewrittenRisks Related to Investing in Litecoin

    We may be subject to regulatory developments related to crypto assets and crypto asset markets, which could adversely affect our business, financial condition and results of operations

    The company added that the SEC issued its Digital Asset Interpretation on March 17, 2026.

  • 34% rewrittenRisks Related to Securities Markets and Investment in our Stock

    Other than as described below or in connection with a strategic transaction we do not intend to pay and we have not paid, any cash dividends on our shares of common stock. Our stockholders will not be able to receive a return on their shares unless the value of our common stock appreciates and they sell their shares

    The capital return is now identified as paid December 6, 2023 under the October 31, 2023 cooperation agreement with Anson Funds and Cable Car Capital.

All 27 risk factors

Headings as the filing states them, in filing order.

Risks Related to Investing in Litecoin

  1. 01The price of Litecoin has been and will likely continue to be, highly volatile
  2. 02The launch of central bank digital currencies (CBDCs) may adversely impact our business
  3. 03We may be subject to regulatory developments related to crypto assets and crypto asset markets, which could adversely affect our business, financial condition and results of operations42% rewritten
  4. 04Regulatory change reclassifying Litecoin as a security could lead to our falling within the definition of “investment company” under the Investment Company Act of 1940, as amended, or the 1940 Act and could adversely affect the market price of Litecoin and the market price of our common stock
  5. 05We are not subject to legal and regulatory obligations that apply to investment companies such as mutual funds and exchange-traded funds, or to obligations applicable to investment advisers

Risks Related to Our Financial Condition and Capital Requirements

  1. 06We have incurred significant losses from our inception and we anticipate that we may incur losses in the foreseeable future89% rewritten
  2. 07We may need to raise additional capital to continue such development of our pre-clinical drug development programs or our Litecoin Treasury StrategyNew

Risks Related to Our Intellectual Property

  1. 08The value of our intellectual property is dependent, in part, on obtaining and maintaining patent protection and preserving trade secrets, which cannot be guaranteed

General Business Risks

  1. 09Our employees, independent contractors, consultants or commercial partners may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business
  2. 10Our business and operations would suffer in the event of system failures
  3. 11Our efforts will be seriously jeopardized if we are unable to retain and attract key employees
  4. 12Negative U.S. and global economic conditions may pose challenges to our business strategy, which relies on funding from the financial markets or collaborators
  5. 13Laws, rules and regulations relating to public companies may be costly and impact our ability to attract and retain directors and executive officers
  6. 14Security breaches and privacy, data protection, cybersecurity, operational resilience and Artificial Intelligence (AI) issues could compromise our information and systems and expose us to liability, which would cause our business and reputation to suffer62% rewritten
  7. 15If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business
  8. 16We or the third parties upon whom we depend may be adversely affected by natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster
  9. 17Limitations on the deductibility of net operating losses could adversely affect our business and financial condition

Risks Related to Securities Markets and Investment in our Stock

  1. 18We are currently operating in a period of capital markets disruption and economic uncertainty45% rewritten
  2. 19If we fail to comply with the continued listing standards of the Nasdaq Capital Market, we may be delisted and the price of our common stock, our ability to access the capital markets and our financial condition could be negatively impacted
  3. 20The trading price of the shares of our common stock has been and may continue to be highly volatile and could decline in value and we may incur significant costs from class action litigation
  4. 21Future sales of our common stock, including common stock issued upon exercise of outstanding warrants or options, may depress the market price of our common stock and cause stockholders to experience dilution55% rewritten
  5. 22Other than as described below or in connection with a strategic transaction we do not intend to pay and we have not paid, any cash dividends on our shares of common stock. Our stockholders will not be able to receive a return on their shares unless the value of our common stock appreciates and they sell their shares34% rewritten
  6. 23We will have broad discretion over the use of the net proceeds from any exercise of outstanding warrants and options
  7. 24We are authorized to issue blank check preferred stock, which could adversely affect the holders of our common stock
  8. 25Anti-takeover provisions contained in our amended and restated certificate of incorporation and sixth amended and restated bylaws, as well as provisions of Delaware law, could impair a takeover attempt
  9. 26Any person or entity purchasing or otherwise acquiring or holding any interest in our shares of capital stock shall be deemed to have notice of and consented to such provisions
  10. 27Our executive officer and directors may sell shares of their stock and these sales could adversely affect our stock price

Other Lite Strategy 10-Ks

  • FY2025 10-K risk factors
    33 risks7 new11 dropped10 reworded

    Lite Strategy added risks regarding its new Litecoin holding strategy and crypto asset market regulations.

    Filed Sep 26, 2025
  • FY2024 10-K risk factors
    37 risks

    Lite Strategy is actively exploring strategic alternatives and has discontinued clinical programs like voruciclib and ME-344, implementing a workforce reduction. Significant risks include potential delisting from Nasdaq, activist pressure from major shareholders Anson Advisors and Cable Car Capital, and the need to secure additional capital if development resumes.

    Filed Sep 19, 2024

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.